Characteristics of patients with cGVHD of whom samples were used for protein microarray
| Patient . | Age (y) . | Recipient sex . | Donor sex/relationship . | GVHD prophylaxis . | Prior acute GVHD (grade) . | Organs affected by cGVHD . | Months after HSCT at cGVHD onset . | Immune suppression day of IgG study . | Cancer type . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | M | M/unrelated | Rapamycin/ FK506 | None | Skin, mouth, eye (SICCA) | 7 | Prednisone 15 mg, rapamycin, MMF | NHL |
| 2 | 55 | F | F/related | CD8 depletion, FK506 | None | Skin | 10 | MMF | ALL |
| 3 | 40 | M | M/related | Rapamycin/ FK506 | None | Mouth, eyes (SICCA), liver | 10 | FK506 | IMF |
| 4 | 53 | F | M/related | Rapamycin/ FK506 | None | Skin, mouth, liver | 7 | Prednisone 20 mg, rapamycin | CML |
| 5 | 30 | M | F/related | Rapamycin/ FK506 | 1 | Skin, liver | 7 | None | AML |
| 6 | 58 | F | M/related | CD8 depletion, FK506 | 2 | Skin, mouth, lung | 9 | None | MDS/ AML |
| 7 | 45 | F | F/unrelated | Rapamycin/ FK506 | 2 | Skin, mouth (scleroderma) | 7 | Prednisone 15 mg, MMF | AML |
| 8 | 50 | F | M/related | Rapamycin/ FK506 | 1 | Liver, muscle | 7 | None | CML |
| 9 | 50 | M | F/related | CD8 depletion, FK506 | 1 | Skin, mouth (scleroderma) | 10 | None | CLL |
| 10 | 62 | M | F/related | Rapamycin/ FK506 | 2 | Skin, mouth | 9 | Rapamycin, FK506 | CLL |
| Patient . | Age (y) . | Recipient sex . | Donor sex/relationship . | GVHD prophylaxis . | Prior acute GVHD (grade) . | Organs affected by cGVHD . | Months after HSCT at cGVHD onset . | Immune suppression day of IgG study . | Cancer type . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 46 | M | M/unrelated | Rapamycin/ FK506 | None | Skin, mouth, eye (SICCA) | 7 | Prednisone 15 mg, rapamycin, MMF | NHL |
| 2 | 55 | F | F/related | CD8 depletion, FK506 | None | Skin | 10 | MMF | ALL |
| 3 | 40 | M | M/related | Rapamycin/ FK506 | None | Mouth, eyes (SICCA), liver | 10 | FK506 | IMF |
| 4 | 53 | F | M/related | Rapamycin/ FK506 | None | Skin, mouth, liver | 7 | Prednisone 20 mg, rapamycin | CML |
| 5 | 30 | M | F/related | Rapamycin/ FK506 | 1 | Skin, liver | 7 | None | AML |
| 6 | 58 | F | M/related | CD8 depletion, FK506 | 2 | Skin, mouth, lung | 9 | None | MDS/ AML |
| 7 | 45 | F | F/unrelated | Rapamycin/ FK506 | 2 | Skin, mouth (scleroderma) | 7 | Prednisone 15 mg, MMF | AML |
| 8 | 50 | F | M/related | Rapamycin/ FK506 | 1 | Liver, muscle | 7 | None | CML |
| 9 | 50 | M | F/related | CD8 depletion, FK506 | 1 | Skin, mouth (scleroderma) | 10 | None | CLL |
| 10 | 62 | M | F/related | Rapamycin/ FK506 | 2 | Skin, mouth | 9 | Rapamycin, FK506 | CLL |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; F, female; M, male; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; NHL, non-Hodgkin lymphoma.